A detailed history of Dsm Capital Partners LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Dsm Capital Partners LLC holds 944,154 shares of NBIX stock, worth $119 Million. This represents 1.69% of its overall portfolio holdings.

Number of Shares
944,154
Previous 997,784 5.37%
Holding current value
$119 Million
Previous $137 Million 20.87%
% of portfolio
1.69%
Previous 2.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$114.58 - $153.15 $6.14 Million - $8.21 Million
-53,630 Reduced 5.37%
944,154 $109 Million
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $18.1 Million - $19.8 Million
-138,218 Reduced 12.17%
997,784 $137 Million
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $11.2 Million - $12.4 Million
-86,007 Reduced 7.04%
1,136,002 $157 Million
Q4 2023

Feb 12, 2024

SELL
$106.07 - $132.76 $212,988 - $266,582
-2,008 Reduced 0.16%
1,222,009 $161 Million
Q3 2023

Nov 13, 2023

BUY
$94.02 - $117.1 $15.4 Million - $19.2 Million
163,747 Added 15.44%
1,224,017 $138 Million
Q2 2023

Aug 11, 2023

SELL
$89.53 - $104.87 $17.8 Million - $20.9 Million
-199,261 Reduced 15.82%
1,060,270 $100 Million
Q1 2023

May 12, 2023

SELL
$94.11 - $123.02 $6.89 Million - $9 Million
-73,172 Reduced 5.49%
1,259,531 $127 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $1.12 Million - $1.33 Million
10,501 Added 0.79%
1,332,703 $159 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $852,013 - $998,104
-9,258 Reduced 0.7%
1,322,202 $140 Million
Q2 2022

Aug 12, 2022

SELL
$75.79 - $100.07 $1.51 Million - $1.99 Million
-19,871 Reduced 1.47%
1,331,460 $130 Million
Q1 2022

May 13, 2022

SELL
$72.45 - $94.81 $4.12 Million - $5.39 Million
-56,866 Reduced 4.04%
1,351,331 $127 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $8.36 Million - $11.1 Million
-104,913 Reduced 6.93%
1,408,197 $120 Million
Q3 2021

Nov 12, 2021

SELL
$86.18 - $99.03 $1.93 Million - $2.22 Million
-22,374 Reduced 1.46%
1,513,110 $145 Million
Q2 2021

Aug 13, 2021

BUY
$89.43 - $102.27 $16.7 Million - $19.1 Million
186,977 Added 13.87%
1,535,484 $149 Million
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $20.3 Million - $27.7 Million
232,127 Added 20.79%
1,348,507 $131 Million
Q4 2020

Feb 12, 2021

BUY
$86.91 - $108.33 $24.3 Million - $30.3 Million
279,614 Added 33.42%
1,116,380 $107 Million
Q3 2020

Nov 13, 2020

SELL
$96.16 - $135.15 $2.77 Million - $3.9 Million
-28,848 Reduced 3.33%
836,766 $80.5 Million
Q2 2020

Aug 13, 2020

BUY
$85.09 - $130.36 $473,185 - $724,931
5,561 Added 0.65%
865,614 $106 Million
Q1 2020

May 14, 2020

BUY
$75.11 - $113.76 $14.2 Million - $21.6 Million
189,504 Added 28.26%
860,053 $74.4 Million
Q4 2019

Feb 13, 2020

BUY
$86.8 - $118.57 $1.68 Million - $2.29 Million
19,336 Added 2.97%
670,549 $72.1 Million
Q3 2019

Nov 13, 2019

SELL
$83.82 - $101.5 $780,448 - $945,066
-9,311 Reduced 1.41%
651,213 $58.7 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $2.58 Million - $3.25 Million
-35,658 Reduced 5.12%
660,524 $55.8 Million
Q1 2019

May 13, 2019

BUY
$69.31 - $91.53 $48.3 Million - $63.7 Million
696,182 New
696,182 $61.3 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Dsm Capital Partners LLC Portfolio

Follow Dsm Capital Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dsm Capital Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dsm Capital Partners LLC with notifications on news.